• FirefoxUpgrade to the new Firefox »
  •  Dow Down1.45% Nasdaq Down1.03%

    More On RHHBY



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Roche Holding AG (RHHBY)

    -Other OTC
    33.76 Down 0.62(1.79%) Jan 30, 3:59PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Roche Holding AG
    Grenzacherstrasse 124
    Basel, 4070
    Switzerland - Map
    Phone: 41 61 688 11 11
    Fax: 41 61 691 93 91
    Website: http://www.roche.com

    Index Membership:N/A
    Full Time Employees:85,080

    Business Summary 

    Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctorsÂ’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Roche Holding AG

    Key Executives 
    Dr. Severin Schwan Ph.D., 48
    Chief Exec. Officer and Director
    Dr. Alan Hippe , 48
    Chief Financial Officer and IT Officer
    Dr. Gottlieb A. Keller , 61
    Gen. Counsel and Corp. Sec.
    Mr. Silvia Ayyoubi , 62
    Head of Group HR
    Mr. Daniel O'Day , 51
    Chief Operating Officer of Pharmaceuticals division
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.